Parallax Volatility Advisers
XBIT icon

Parallax Volatility Advisers’s XBiotech XBIT Stock Holding History

Parallax Volatility Advisers’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15,000
Closed -$247K – 4209
2017
Q1 		$247K Hold
15,000
– – ﹤0.01% 1856
2016
Q4 		$152K Buy
+15,000
New +$200K ﹤0.01% 2012

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Parallax Volatility Advisers's XBIT Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of XBiotech (XBIT) in Q1 2018, closing a stake of 3,192 shares — an estimated $13K sold.

Parallax Volatility Advisers first reported a position in XBIT in Q1 2017 and held it in 2 quarters. The position peaked at $52K in Q1 2017. 43 funds tracked by Wall St. Rank hold XBIT as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining XBiotech position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 3,192 XBiotech shares in Q1 2018, an estimated $13K.
  • Parallax Volatility Advisers first reported a position in XBiotech in Q1 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's XBiotech position peaked at $52K in Q1 2017.
  • 43 funds tracked by Wall St. Rank held XBiotech as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.